

UnitedHealthcare Pharmacy
Clinical Pharmacy Programs

| | |
|-------------------|--|
| Program Number | 2026 P 1377-5 |
| Program | Prior Authorization/Notification |
| Medication | Tavneos® (avacopan) |
| P&T Approval Date | 1/2022, 1/2023, 1/2024, 1/2025, 1/2026 |
| Effective Date | 4/1/2026 |

1. Background:

Tavneos (avacopan) is a complement 5a receptor (C5aR) antagonist indicated as an adjunctive treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (granulomatosis with polyangiitis [GPA] and microscopic polyangiitis [MPA]) in combination with standard therapy including glucocorticoids. Tavneos does not eliminate glucocorticoid use.

2. Coverage Criteria^a:

A. Anti-Neutrophil Cytoplasmic Autoantibody (ANCA) - Associated Vasculitis

1. Initial Authorization

a. **Tavneos** will be approved based **all** of the following criteria:

(1) Diagnosis of severe active ANCA-associated vasculitis

-AND-

(2) Disease is **one** of the following types:

(a) Granulomatosis with polyangiitis (GPA)

(b) Microscopic polyangiitis (MPA)

-AND-

(3) Used as adjunctive treatment in combination with standard therapy (e.g., prednisone, azathioprine, mycophenolate, methotrexate, rituximab, cyclophosphamide)

Authorization will be issued for 6 months.

2. Reauthorization

a. **Tavneos** will be approved based on **both** of the following criteria:

(1) Patient does not show evidence of progressive disease while on Tavneos therapy

-AND-

(2) Used as adjunctive treatment in combination with standard therapy (e.g., prednisone, azathioprine, mycophenolate, methotrexate, rituximab, cyclophosphamide)

Authorization will be issued for 12 months.

^a State mandates may apply. Any federal regulatory requirements and the member specific benefit plan coverage may also impact coverage criteria. Other policies and utilization management programs may apply.

3. Additional Clinical Rules:

- Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic. Use of automated approval and re-approval processes varies by program and/or therapeutic class.
- Supply limits may be in place.
- Medical Necessity may be in place.

4. References:

1. Tavneos [package insert]. Cincinnati, OH: Thermo Fisher Scientific; June 2024.

| Program | Prior Authorization/Notification – Tavneos [®] (avacopan) |
|-----------------------|--|
| Change Control | |
| 12/2021 | New program |
| 1/2023 | Annual review with no change to coverage criteria. Added state mandate footnote. |
| 1/2024 | Annual review with no changes. |
| 1/2025 | Annual review with no changes to coverage criteria. Updated reference. |
| 1/2026 | Annual review with no changes to coverage criteria. |